Pharmanovia Acquires Global CNS Portfolio from Sanofi

Funds Advised by Permira Acquire Neuraxpharm from Funds Advised by Apax Partners

September 22, 2020

Pharmaceuticals

Funds advised by Permira have agreed to acquire the controlling stake in Neuraxpharm, a leading European specialty pharmaceuticals company focused on central nervous system (CNS) disorders, from funds advised by Apax Partners. Financial terms were not disclosed; Neuraxpharm had annual revenues in excess of €460 million and around 850 employees under Apax's ownership.

CBC Group and Mubadala Acquire UCB's Mature China Neurology & Allergy Portfolio to Create NeuroGen Pharma

November 29, 2024

Pharmaceuticals

CBC Group, in partnership with Mubadala Investment Company, has completed the US$680 million acquisition of UCB’s mature neurology and allergy product portfolio in China, including brands such as Keppra, Vimpat, Neupro, Zyrtec and Xyzal and a manufacturing site in Zhuhai. The assets have been combined into a new company named NeuroGen Pharma as an anchor platform to build an integrated CNS biopharma business in China and expand capability in neurology and allergy treatments.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Amneal Acquires Saol Therapeutics' Baclofen Franchise

January 5, 2022

Pharmaceuticals

Amneal Pharmaceuticals has agreed to acquire Saol Therapeutics' Baclofen franchise, including Lioresal and LYVISPAHTM, for approximately $83.5 million in cash plus certain low double-digit royalties. The deal expands Amneal's neurology and specialty portfolio, adds institutional commercial infrastructure ahead of its planned biosimilars launches, and is expected to be accretive to Amneal's 2022 adjusted EBITDA and EPS.

Clario Acquires NeuroRx

March 19, 2025

Healthcare Services

Clario has acquired NeuroRx, a Montreal-based imaging analysis provider specializing in neuroimaging for clinical trials, to strengthen Clario's neuroscience capabilities. NeuroRx founder Douglas Arnold will join Clario as Senior Scientific Advisor as the company integrates NeuroRx's imaging expertise to support drug development in CNS indications.